In breast cancer, intratumoral heterogeneity of HMCN1 mutant alleles is associated with a poor patient prognosis (28), and mutations in HMCN1 occur in approximately 60% of patients, regardless of the MSI status in GC patients (29). This evidence concerns the gene HMCN1 and gastric cancer.